Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

High prevalence of cisplatin-induced ototoxicity in Cape Town, South Africa

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • Contributors:
      MRC Human Genetics Research Unit; National Research Foundation.
    • بيانات النشر:
      South African Medical Association
    • الموضوع:
      2014
    • Collection:
      South African Medical Journal (SAMJ)
    • الموضوع:
      Africa; South Africa; Western Cape; Cape Town; Groote Schuur Hospital; Age; Gender; Cumulative Cisplatin Dosage; Tumour Site; Audiological Monitoring
    • الموضوع:
      Cape Town; Audiological Monitoring
    • نبذة مختصرة :
      Background. Cisplatin is administered as the first-line treatment of soft-tissue cancers. It has a reported cure rate of up to 85%, but is associated with a high incidence of ototoxicity, characterised by irreversible bilateral hearing loss and affecting 23 - 50% of adults who receive the drug.Objectives. To determine the incidence of cisplatin-induced ototoxicity at Groote Schuur Hospital (GSH), Cape Town, South Africa.Methods. A retrospective cross-sectional study of cisplatin-receiving cancer patients attending GSH between January 2006 and August 2011.Results. A total of 377 patients were recorded as receiving cisplatin therapy during the study period. A 300% increase in new cisplatin-receiving patients receiving audiological monitoring was observed between 2006 and 2010. However, only patients with all clinical data as well as baseline and follow-up audiometric analyses were investigated. One hundred and seven such patients were identified, 55.1% of whom developed cisplatin-induced ototoxicity while receiving high-dose (≥60 mg/m2) cisplatin treatment. Higher cumulative cisplatin dosages were associated with development of significant hearing loss (p=0.027). The odds of developing cisplatin-induced hearing loss were elevated for patients with head and neck tumours and lymphoma (p=0.0465 and p=0.0563, respectively) and were significantly lower for those with reproductive cancers (p=0.0371).Conclusion. Comprehensive audiological monitoring should be available for every patient during cisplatin treatment to minimise the development of disabling hearing loss.
    • File Description:
      application/pdf
    • Relation:
      http://samj.org.za/index.php/samj/article/view/7389/5902; http://samj.org.za/index.php/samj/article/downloadSuppFile/7389/5160; http://samj.org.za/index.php/samj/article/downloadSuppFile/7389/4643; http://samj.org.za/index.php/samj/article/downloadSuppFile/7389/4644; http://samj.org.za/index.php/samj/article/downloadSuppFile/7389/4645; http://samj.org.za/index.php/samj/article/view/7389
    • الرقم المعرف:
      10.7196/SAMJ.7389
    • Rights:
      Copyright of published material remains in the Authors’ name. This allows authors to use their work for their own non-commercial purposes without seeking permission from the Publisher, subject to properly acknowledging the Journal as the original place of publication. Authors are free to copy, print and distribute their articles, in full or in part, for teaching activities, and to deposit or include their work in their own personal or institutional database or on-line website. Authors are requested to inform the Journal/Publishers of their desire/intention to include their work in a thesis or dissertation or to republish their work in any derivative form (but not for commercial use). Material submitted for publication in the SAMJ is accepted provided it has not been published or submitted for publication elsewhere. Please inform the editorial team if the main findings of your paper have been presented at a conference and published in abstract form, to avoid copyright infringement.
    • الرقم المعرف:
      edsbas.DC259424